Diabetes & Endocrinology Clinical Trials Update: Week 40, 2026

Published October 2, 2026 — 5 trials covered

By Victor Lafforgue, Founder of TrialsAlert. Blog posts are AI-drafted from ClinicalTrials.gov source data and reviewed by the editorial team. See our editorial policy for details.

A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity

This large international Phase 3 study is examining tirzepatide, a medication for adults with obesity or who are overweight. The trial aims to find out if tirzepatide can lower the risk of serious health problems and death related to obesity. If successful, this treatment could provide new hope for people struggling with obesity by potentially improving long-term health outcomes.

Teplizumab in Pediatric Stage 2 Type 1 Diabetes

This Phase 4 study tested teplizumab, an immunotherapy, in children under 8 years old with early-stage type 1 diabetes. The goal was to assess safety and how the drug works in the body, with the hope that it might delay the progression of the disease. The trial has finished enrolling and results are awaited, which could lead to new ways to help young children manage type 1 diabetes earlier.

Long Term Comparative Effectiveness of Once Weekly Semaglutide Versus Standard of Care in a Real World Adult US Population With Type 2 Diabetes - a Randomized Pragmatic Trial

This Phase 4 trial studied the effects of once-weekly semaglutide injections compared to usual diabetes treatments in adults with type 2 diabetes. With more than 1,200 participants across the US and Canada, the trial looked at whether semaglutide could better control blood sugar with less frequent dosing. The findings may help guide treatment choices for people living with type 2 diabetes seeking convenient and effective options.

A Study to Evaluate Effect of AZD6234 in Adult Participants With Type 2 Diabetes Mellitus and Obesity or Overweight

This ongoing Phase 3 trial is testing AZD6234, an oral medication, in adults who have type 2 diabetes along with obesity or overweight. The study aims to see if the drug can reduce body weight while improving diabetes management. Results expected after over a year of treatment could offer a new oral therapy option for people facing both conditions.

A Study to Evaluate Effect of AZD6234 in Adult Participants With Obesity or Overweight With Weight-related Comorbidity Without Type 2 Diabetes Mellitus

This Phase 3 trial is evaluating AZD6234 in adults with obesity or overweight who have related health problems but do not have type 2 diabetes. The goal is to measure whether the drug can help reduce weight and improve associated health issues. If successful, this could add a valuable treatment option for those managing obesity and its complications without diabetes.

TrialsAlert subscribers received the full impact-classified briefing and doctor-ready report this week. Get weekly briefings at trialsalert.com.